Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8985)
All Articles published online
|
Publishing Process of This Article
|
Oct 7, 2019 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603 [PMID: 31602160 DOI: 10.3748/wjg.v25.i37.5590] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm |
| Number | Citing Articles |
| 1 |
Caixia Liang, Tomohiko Fukuda, Tomoya Isaji, Chengwei Duan, Wanli Song, Yuqin Wang, Jianguo Gu. α1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma. Biochimica et Biophysica Acta (BBA) - General Subjects 2021; 1865(6): 129870 doi: 10.1016/j.bbagen.2021.129870
|
| 2 |
Antara Sharma, Pranish Bomzan, Niloy Roy, Vikas Kumar Dakua, Kanak Roy, Abhinath Barman, Rabindra Dey, Abhijit Chhetri, Rajani Dewan, Ankita Dutta, Anoop Kumar, Mahendra Nath Roy. Exploring the Inclusion Complex of an Anticancer Drug with β-Cyclodextrin for Reducing Cytotoxicity Toward the Normal Human Cell Line by an Experimental and Computational Approach. ACS Omega 2023; 8(32): 29388 doi: 10.1021/acsomega.3c02783
|
| 3 |
Zhonghan Wu, Jingjing Zheng, Haoke Zhang, Ningzhe Shen, Xiaohui Luo, Chenfang Shen, Peining Song, Yu Zhang, Min Zhang, Shaopeng Yang, Gangqiang Guo, Xiangyang Xue, Fabiao Zhang, Shiyu Feng. Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. International Immunopharmacology 2023; 116: 109737 doi: 10.1016/j.intimp.2023.109737
|
| 4 |
Fadian Ding, Xiaoping Hong, Xiangqun Fan, Shirong Huang, Wei Lian, Xingting Chen, Qicai Liu, Youting Chen, Feng Gao, Nicola Silvestris. DDIT4 Novel Mutations in Pancreatic Cancer. Gastroenterology Research and Practice 2021; 2021: 1 doi: 10.1155/2021/6674404
|
| 5 |
Jian Zhang, Jiangwei Li, Yongqiang Xiong, Ren Li. Circ_0000284 upregulates RHPN2 to facilitate pancreatic cancer proliferation, metastasis, and angiogenesis through sponging miR‐1179. Journal of Biochemical and Molecular Toxicology 2023; 37(3) doi: 10.1002/jbt.23274
|
| 6 |
Yang Yang, Guoying Zhang, Jian Li, Rui Gong, Yingbao Wang, Yang Qin, Qinrong Ping, Libing Hu. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155–5p to regulate WEE1 expression. Pathology - Research and Practice 2021; 228: 153676 doi: 10.1016/j.prp.2021.153676
|
| 7 |
Qiao Yang, Yue Hua Nie, Man Bo Cai, Zhi Min Li, Hong Bo Zhu, Ye Ru Tan. Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma. Drug Design, Development and Therapy 2022; : 1191 doi: 10.2147/DDDT.S353898
|
| 8 |
Zhe Yang, Feiran Chen, Dafu Wei, Fengping Chen, Haixing Jiang, Shanyu Qin. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12005-2
|
| 9 |
Haolin Song, Chen Jiang. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma. Expert Opinion on Drug Delivery 2022; 19(3): 281 doi: 10.1080/17425247.2022.2045943
|
| 10 |
Jing Cui, Yao Guo, Tao Yin, Shanmiao Gou, Jiongxin Xiong, Xueyi Liang, Chong Lu, Tao Peng. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2. Biomedicine & Pharmacotherapy 2023; 166: 115359 doi: 10.1016/j.biopha.2023.115359
|
| 11 |
H.D. RAUB, N. RAJAN, K.J. MCINNES, J.B. WEST. Excess energy and photosynthesis: responses to seasonal water limitations in co-occurring woody encroachers of the semi-arid Southern Great Plains. Photosynthetica 2023; 61(3): 285 doi: 10.32615/ps.2023.018
|
| 12 |
Bing Qi, Han Liu, Ying Dong, Xueying Shi, Qi Zhou, Fen Zeng, Nabuqi Bao, Qian Li, Yuan Yuan, Lei Yao, Shilin Xia. The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma. PeerJ 2020; 8: e9736 doi: 10.7717/peerj.9736
|
| 13 |
Bo Ma, Riyue Yu. Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy. Frontiers in Genetics 2023; 14 doi: 10.3389/fgene.2023.1105900
|
| 14 |
Hongqiao Cai, Ruobing Wang, Xingren Guo, Meiyu Song, Fei Yan, Bai Ji, Yahui Liu. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. Molecular Pharmaceutics 2021; 18(7): 2495 doi: 10.1021/acs.molpharmaceut.0c01225
|
| 15 |
Yao Guo, Heshui Wu, Jiongxin Xiong, Shanmiao Gou, Jing Cui, Tao Peng. miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR/AKT/PI3K pathway in pancreatic cancer. Cell Biology and Toxicology 2023; 39(4): 1203 doi: 10.1007/s10565-022-09736-y
|
| 16 |
Xin Liu, Xu-ying Huang, Zhong Liu, Li Liu, Han Tu. Bioinformatics, Molecular Docking Simulation and in vitro Experiments Reveal the Bioactive Compounds and Mechanism of Coptis chinensis Franch. Against Colorectal Adenocarcinoma. Pharmacognosy Magazine 2023; 19(4): 967 doi: 10.1177/09731296231189553
|
| 17 |
Feng Yang, Ziyu Zhao, Shaoyi Cai, Li Ling, Leying Hong, Liang Tao, Qin Wang. Detailed Molecular Mechanism and Potential Drugs for COL1A1 in Carboplatin-Resistant Ovarian Cancer. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.576565
|
| 18 |
Peng Xing, Shuo Wang, Yu Cao, Bo Liu, Feifei Zheng, Wei Guo, Junhao Huang, Zimo Zhao, Ziyi Yang, Xingda Lin, Liang Sang, Zhe Liu. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs. Drug Resistance Updates 2023; 71: 101002 doi: 10.1016/j.drup.2023.101002
|
| 19 |
Jingjing Yao, Min Huang, Qinghong Shen, Ming Ding, Shaofang Yu, Yajuan Guo, Yuefang Lin, Yaqiu Zheng, Wenbo Chen, Wenxin Yan, Zhongqiu Liu, Dawei Wang, Ming Hu, Linlin Lu. c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.851512
|
| 20 |
Sarah E. Huff, Jordan M. Winter, Chris G. Dealwis. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules 2022; 12(6): 815 doi: 10.3390/biom12060815
|
| 21 |
Rongxiang Wu, Zhan Su, Le Zhao, Ruifeng Pei, Yiren Ding, Deqiang Li, Shuo Zhu, Lu Xu, Wei Zhao, Wuyuan Zhou, Mahmood S. Choudhery. Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis. Stem Cells International 2023; 2023: 1 doi: 10.1155/2023/6510571
|
| 22 |
Céline Hubeau, Natacha Rocks, Didier Cataldo. ADAM28: Another ambivalent protease in cancer. Cancer Letters 2020; 494: 18 doi: 10.1016/j.canlet.2020.08.031
|
| 23 |
Junqiang Li, Yang Song, Chao Zhang, Ronglin Wang, Lei Hua, Yongdong Guo, Dongxue Gan, Liaoliao Zhu, Shanshan Li, Peixiang Ma, Cheng Yang, Hong Li, Jing Yang, Jingjie Shi, Xiaonan Liu, Haichuan Su. TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis. Cellular & Molecular Biology Letters 2022; 27(1) doi: 10.1186/s11658-022-00321-z
|
| 24 |
Chaoyang Zhang, Fawaz N. Al-Shaheri, Mohamed Saiel Saeed Alhamdani, Andrea S. Bauer, Jörg D. Hoheisel, Miriam Schenk, Ulf Hinz, Philipp Goedecke, Karam Al-Halabi, Markus W. Büchler, Nathalia A. Giese, Thilo Hackert, Susanne Roth. Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN). Clinical Cancer Research 2023; 29(8): 1535 doi: 10.1158/1078-0432.CCR-22-2531
|